Other genomic alterations identified in this patient were EGFR A1118T, which was not an actionable driver, and CDKN2A/B loss, which was a variant of unknown significance; microsatellite status was stable, and tumor mutation burden was low (three mutations per megabase). Here, CDKN2A is linked to neoplasm.